

News Release

P123/25e June 17, 2025

BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America

- New Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan expands BASF's existing network of poloxamers sites
- Production capabilities are unique to industry and enable closer collaboration with customers on product development

Florham Park, NJ, June 17, 2025 – BASF opens its new Good Manufacturing Practice (GMP) Solution Center, in Wyandotte, Michigan. This investment underscores the ongoing commitment of BASF to providing innovative solutions in the biopharma and pharmaceutical ingredients industries, including the reliable supply of bioprocessing ingredients and excipients for biopharma applications as well as small molecules.

This new facility will play a crucial role in the expansion of BASF's existing network of GMP sites, with innovative systems and processes that ensure products are produced consistently and controlled according to high quality standards. These practices are crucial in the pharmaceutical industry, where the quality of products is paramount for safety and efficacy.

Featuring state-of-the-art clean room packaging, and high-sensitivity analytical testing, this new facility enables close collaboration with customers on customized chemistries for product development. Additionally, improved manufacturing capabilities will allow for more tightly controlled parameters beyond compendial limits and a validated control system that allows for high reproductivity.

Marion Kuhn, vice president of business management, BASF Pharma Solutions states, "Our new GMP Solution Center exemplifies BASF's dedication to understanding and addressing the evolving needs of our customers in both the biopharma and pharmaceutical industries. This state-of-the-art

Page 2 P123/25e

facility will play a fundamental role in enabling us to collaborate closely with our customers worldwide on product development and GMP manufacturing in ways that are unique to the industry, further strengthening our position as an innovator in the pharmaceutical sector."

"Wyandotte's new GMP Solution Center is a key example of BASF's commitment to innovative excellence," said Benjamin Knudsen, vice president of research North America at BASF Corporation. "This expansion not only showcases our dedication to developing customized solutions, but it also highlights our ability to adapt and innovate in response to our customers' needs. Together, we are paving the way for new innovative solutions."

About BASF Pharma Solutions

BASF Pharma Solutions produces innovative excipients and active ingredients of outstanding quality and performance. With a global team of industry experts and digital solutions, such as the Virtual Pharma Assistants, BASF supports its customers in developing efficient, cost-effective and reliable formulations. Equipped with an in-depth understanding of multiple technologies and applications, BASF has the knowledge and resources to make drug delivery and drug and biologics manufacturing safer and more sustainable. Visit pharma.basf.com to learn more.

About BASF

At BASF, we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers' green transformation. We combine economic success with environmental protection and social responsibility. Around 112,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of €65.3 billion in 2024. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at www.basf.com.